Skip to main content

Tyvaso

Generic name: treprostinil
Treatment for: Pulmonary Arterial Hypertension

Update: Tyvaso Now FDA Approved - July 30, 2009

United Therapeutics Announces Probable Delay in Tyvaso Approval

United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)

SILVER SPRING, Md., March 16, 2009 /PRNewswire-FirstCall/ -- United Therapeutics Corporation announced today that, based on its most recent interactions with the U.S. Food and Drug Administration (FDA), the FDA's pending regulatory review of the New Drug Application (NDA) for Tyvaso (inhaled treprostinil) will likely extend beyond its originally anticipated April 30, 2009, action date. The probable delay relates to questions received from the FDA concerning human factors testing and the instructions for use (IFU) of the OptiNeb portable nebulizer that delivers Tyvaso.

"In response to FDA comments related to our originally submitted instructions for the OptiNeb nebulizer, we provided the FDA with a revised IFU. Following our most recent discussion with the FDA, we have agreed to conduct human factors testing to validate that the revised IFU results in the proper use of the device by a naive user. This relatively small study in normal subjects will test the new IFU in its ability to guide patients to accomplish such tasks as proper device assembly, drug administration, disassembly and cleaning, among other things," said Roger Jeffs, Ph.D., United Therapeutics' President and Chief Operating Officer. "We are working to get the human factors testing conducted and submitted to the FDA as rapidly as possible, but it is a challenge to complete the study and have it properly reviewed by the FDA in advance of the April 30th action date."

Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer, said, "Given the need to conduct this additional study, we are of the opinion that additional review time is likely. Accordingly, we felt it was our responsibility to inform our shareholders in advance of any formal notice from the FDA. We hope that any delay related to this issue will be limited to just a few months. However, in deference to the regulatory process, we will not be providing further information or status updates on any other aspect of our Tyvaso NDA until we receive a definitive written response from the FDA."

A half-hour teleconference will be held on Monday, March 16, 2009, at 9:00 a.m. Eastern Time to answer questions relating to the probable delay. The teleconference is accessible by dialing 877-852-6578, with international callers dialing 719-325-4820. A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 888-203-1112, with international callers dialing 719-457-0820, and using passcode: 4242990.

The teleconference is also being web cast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.

CONTACT: Andrew Fisher, +1-202-483-7000, Afisher@unither.com

Web site: http://www.unither.com/

Ticker Symbol: (NASDAQ-NMS:UTHR)

Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

***

Posted: March 2009

Related articles

Tyvaso (treprostinil) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.